Once-Daily 0.1% Mometasone Furoate Cream versus Twice-Daily 0.1% Betamethasone Valerate Cream in the Treatment of a Variety of Dermatoses

Abstract

A randomized, investigator-blind, parallel-group trial was conducted to compare the safety and efficacy of 0.1% mometasone furoate cream applied once daily with that of 0.1% betamethasone valerate cream applied twice daily in patients (n = 69) with allergic contact dermatitis, atopic dermatitis and other steroid-responsive dermatoses. After 3 days' treatment improvement in conditions averaged 38.2 % and 39.3%, respectively, in the mometasone and betamethasone treatment groups, and after 21 days average improvements were 93.6% and 96.5%, respectively. The physicians' global evaluation of overall change in disease status and the patients' evaluation of treatment also indicated that the two treatment regimens produced comparable, rapid and progressive improvements in the patients' conditions, and no local side-effects were reported. It is concluded that mometasone furoate was as effective as betamethasone valerate in the treatment of a variety of steroid-responsive dermatoses, although mometasone furoate was applied only half as frequently.

Keywords

Mometasone furoate betamethasone valerate steroid-responsive dermatoses allergic contact dermatitis atopic dermatitis

Get full access to this article

View all access options for this article.

References

Cornell

Stoughton

: The use of topical steroids in psoriasis. Dermatol Clin 1984; 2: 397–409.

Bressinck

Williams

Peets

: Comparison of the effect of mometasone furoate ointment 0.1%, and hydrocortisone ointment 0.1%, on adrenocortical function in psoriasis patients. Today Ther Trends 1988; 5: 25–35.

Medansky

Bressinck

Cole

: Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis 1988; 42: 480–485.

Rosenthal

Duke

: A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1% vs betamethasone valerate ointment 0.1% in the treatment of psoriasis. Curr Ther Res 1988; 44: 790–801.

Medansky

Brody

Kanof

: Clinical investigations of mometasone furoate – a novel, nonfluorinated, topical corticosteroid. Semin Dermatol 1987; 6: 94–100.

Sefton

Kyriakopoulos

: Comparative efficacy of hydrocortisone valerate 0.2 percent ointment in the treatment of atopic dermatitis. Cutis 1983; 32: 89–91.

Fredriksson

: A double-blind comparison between amcinonide and betamethasone valerate in the treatment of psoriasis. Curr Ther Res 1981; 29: 486–491.

Vollum

Sparkes

: Influence of the base on the results of clinical trials with topical corticosteroids. Dermatologica 1979; 158: 293–298.

Vickers

CFH

: Existence of reservoir in the stratum corneum. Arch Dermatol 1963; 88: 72–75.